Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 23 | -0.41 Increased by +43.06% | -0.47 Increased by +12.77% |
| Aug 10, 23 | -0.76 Increased by +21.65% | -0.47 Decreased by -61.70% |
| May 8, 23 | -0.36 Increased by +65.05% | -0.54 Increased by +33.33% |
| Mar 7, 23 | 4.65 Increased by +711.84% | 4.84 Decreased by -3.93% |
| Nov 8, 22 | -0.72 Increased by +38.46% | -0.92 Increased by +21.74% |
| Aug 4, 22 | -0.97 Increased by +25.95% | -0.96 Decreased by -1.04% |
| May 4, 22 | -1.03 Decreased by -18.39% | -1.67 Increased by +38.32% |
| Feb 24, 22 | -0.76 Decreased by -2.70% | -1.14 Increased by +33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 16.51 M Increased by +527.37% | -28.69 M Increased by +40.04% | Decreased by -173.80% Increased by +90.44% |
| Jun 30, 23 | 7.00 M Increased by +28.67% | -51.15 M Increased by +20.84% | Decreased by -730.53% Increased by +38.48% |
| Mar 31, 23 | 35.58 M Increased by +1.76 K% | -24.35 M Increased by +66.47% | Decreased by -68.45% Increased by +98.19% |
| Dec 31, 22 | 402.49 M Increased by +1.93 K% | 309.43 M Increased by +890.33% | Increased by +76.88% Increased by +139.02% |
| Sep 30, 22 | 2.63 M Decreased by -40.14% | -47.85 M Increased by +21.02% | Decreased by -1.82 K% Decreased by -31.94% |
| Jun 30, 22 | 5.44 M Increased by +207.28% | -64.62 M Increased by +4.30% | Decreased by -1.19 K% Increased by +68.86% |
| Mar 31, 22 | 1.92 M Increased by +197.52% | -72.63 M Decreased by -62.87% | Decreased by -3.79 K% Increased by +45.26% |
| Dec 31, 21 | 19.87 M Increased by +26.72% | -39.15 M Decreased by -3.32% | Decreased by -197.04% Increased by +18.47% |